HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Deloron, P. Articles by Sezibera, C. Search for Related Content PubMed PubMed Citation Articles by Deloron, P. Articles by Sezibera, C.

Amodiaquine and Sulfadoxine-Pyrimethamine as Treatment for Chloroquine-Resistant Plasmodium falciparum in Rwanda

Philippe Deloron^*, John D. Sexton^*, Laurent Bugilimfura AND Célestin Sezibera

^* Malaria Branch, Division of Parasitic Diseases, Center for Infectious Diseases, Centers for Disease Control, Atlanta, Georgia
and Combatting Childhood Communicable Diseases Program
and Ministry of Health Kigali, Rwanda

The efficacy of amodiaquine and sulfadoxine-pyrimethamine combination as a second-line therapy for chloroquine-resistant Plasmodium falciparum infections was investigated in Rwanda in September 1986. Children 5 years old presenting with a P. falciparum parasitemia 14 days after treatment with chloroquine were administered either amodiaquine (25 mg/kg over 3 days, 64 patients) or sulfadoxine-pyrimethamine (as a single dose with tablets containing 500 mg of sulfadoxine and 25 mg of pyrimethamine: tablet for children under 1 year, for those 1–3 years old, and 1 tablet for those 4–5 years old; 34 patients) and followed for 7 days. Seven days after starting treatment with amodiaquine, 50 (76%) children were aparasitemic. All the children who had received sulfadoxine-pyrimethamine were aparasitemic 7 days after initiation of therapy.

Accepted for publication August 11, 1987.